syn818
Advanced Solid Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Advanced Solid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mhb046c Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1/2 | CC |
Arv-806 Arvinas Inc. | Phase 1/2 | CC |
Orb-011 Orionis Biosciences Inc | Phase 1 | CC |
Henatinib Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | CC |
bi 3819026 Boehringer Ingelheim | Phase 1 | CC |
View all 21 →
Same molecule, other indications
syn818 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →